View Older Stories View More Recent Stories

Sep 10, 2020 04:15PM Bristol Myers Squibb Announces Quarterly Dividend for Third Quarter 2020
Sep 10, 2020 06:59AM Bristol Myers Squibb to Participate in Morgan Stanley’s 18th Annual Global Healthcare Virtual Conference
Sep 8, 2020 07:00AM Bristol-Myers Squibb (BMY) Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need
Sep 8, 2020 06:59AM Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need
Sep 3, 2020 01:00AM Press news Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2020 RESULTS
Sep 2, 2020 06:59AM Bristol Myers Squibb to Participate in Citi’s 15th Annual BioPharma Virtual Conference
Sep 1, 2020 12:51PM Bristol-Myers Squibb (BMY) Announces FDA Approves Onureg as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
Sep 1, 2020 12:50PM U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
Sep 1, 2020 09:13AM Bristol-Myers Squibb (BMY) Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia in Patients with Relapsing Forms of Multiple Sclerosis
Sep 1, 2020 09:00AM Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
Aug 25, 2020 07:00AM Bristol-Myers Squibb (BMY) Phase 3 IDHENTIFY Trial in Patients with R/R Acute Myeloid Leukemia Did Not Meet Primary Endpoint
Aug 25, 2020 06:59AM Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Aug 24, 2020 06:59AM Bristol-Myers Squibb (BMY) to Acquire Forbius
Aug 24, 2020 06:59AM Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
Aug 17, 2020 07:00AM Bristol-Myers Squibb (BMY) Enters Exclusive Global License for Dragonfly's IL-12 Investigational Immunotherapy Program
Aug 17, 2020 06:59AM Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program
Aug 12, 2020 06:59AM Bristol Myers Squibb and the Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts
Aug 11, 2020 07:00AM Bristol-Myers Squibb (BMY) CheckMate -649, Phase 3 Trial Evaluating Opdivo Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints
Aug 11, 2020 06:59AM CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First
Aug 11, 2020 06:59AM CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Surv
Aug 8, 2020 07:00AM Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
Aug 6, 2020 06:59AM Bristol Myers Squibb Reports Second Quarter 2020 Financial Results
Jul 30, 2020 08:34AM Bristol-Myers Squibb (BMY) Announces Paula A. Price and Derica W. Rice to Board
Jul 30, 2020 06:59AM Bristol Myers Squibb Board Elects Two New Independent Directors
Jul 29, 2020 04:20PM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announce Submission of BLA to FDA for Idecabtagene Vicleucel for Adults with R/R Multiple Myeloma
Jul 29, 2020 04:16PM Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple My
Jul 17, 2020 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)
Jul 16, 2020 06:59AM Bristol Myers Squibb Announces Expiration and Final Results of Registered Exchange Offers
Jul 14, 2020 10:00AM ReviveMed Announces AI-driven Metabolomics Study with Bristol Myers Squibb
Jun 26, 2020 09:17AM Bristol-Myers Squibb (BMY) Announces EMA Approves Reblozyl for Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia
Jun 26, 2020 09:05AM European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia
Jun 18, 2020 06:59AM Bristol Myers Squibb to Announce Results for Second Quarter 2020 on August 6, 2020
Jun 16, 2020 06:59AM Bristol Myers Squibb Announces Commencement of Registered Exchange Offers
Jun 11, 2020 04:15PM Bristol Myers Squibb Announces Dividend
Jun 10, 2020 07:52PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based C
Jun 4, 2020 06:59AM Bristol Myers Squibb to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
Jun 3, 2020 07:00AM Bristol-Myers Squibb (BMY) Announces New Data Reinforce Improved and Durable Clinical Responses of Orencia in Moderate-to-Severe Early Rheumatoid Arthritis Patients with Autoantibodies Linked to More
Jun 3, 2020 06:59AM New Data Reinforce Improved and Durable Clinical Responses of Orencia in Moderate-to-Severe Early Rheumatoid Arthritis Patients with Autoantibodies Linked to More Severe Disease
Jun 2, 2020 06:59AM Bristol Myers Squibb Announces Positive Topline Results from Pivotal Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Patients with Moderate to Severe Ulcerative Colitis
Jun 1, 2020 07:00AM Bristol-Myers Squibb (BMY) Announces Commercial Launch and Availability of ZEPOSIA, New Oral Treatment for Relapsing Forms of MS
Jun 1, 2020 06:59AM Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
May 29, 2020 06:59AM Bristol Myers Squibb to Hold Virtual Three-Part Investor Series
May 27, 2020 07:00AM Bristol-Myers Squibb (BMY) Granted European Commission Approval for Zeposia (ozanimod) for Treatment of Adult Patients with RRMS with Active Disease
May 27, 2020 06:59AM Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
May 26, 2020 05:48PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
May 22, 2020 07:00AM Bristol-Myers Squibb (BMY) Announces EMA Validates its Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486
May 22, 2020 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486
May 20, 2020 06:59AM Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases
May 15, 2020 03:57PM Bristol-Myers Squibb (BMY) Announces FDA Approves Opdivo + Yervoy as First-Line Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1≥1%
May 15, 2020 03:56PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1≥1%
View More Recent Stories View Older Stories